8-Kfiled October 3, 2023, 7:59 PM ETticker KZRCIK 0001645666
other materialconfidence highsentiment negativemateriality 0.80
Kezar Life Sciences, Inc. (KZR): restructuring charge — Kezar Life Sciences cuts workforce 41%, appoints Christopher Kirk as CEO, extends cash runway to late 2026
Kezar Life Sciences, Inc.
Workforce reduction of ~41%, pausing all research and drug discovery; severance charge of $2.9M-$3.2M expected in Q4 2023.
CEO John Fowler resigns Nov 7; co-founder Christopher Kirk appointed CEO with $600k salary, $75k bonus, 875k stock options.
CMO Noreen Roth Henig steps down Oct 6; Zung To assumes clinical operations oversight.
Cash runway extended to late 2026; PALIZADE Phase 2b LN data mid-2026. KZR-261 Phase 1 data 2024, PORTOLA AIH data mid-2025.
Exploring strategic partnering for protein secretion platform and preclinical programs.
Christopher Kirk, Ph.D., the Company’s co-founder and member of the Board, has been appointed to serve as Chief Executive Officer, effective as of the Effective Date.
On September 30, 2023, John Fowler, the Company’s co-founder, Chief Executive Officer and member of the Board, notified the Board that he will resign and cease serving as Chief Executive Officer, effective November 7, 2023
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Christopher Kirk was appointed as Chief Executive Officer at Kezar Life Sciences, Inc..
Action
appointed
Role
Chief Executive Officer
Exact text from the filing
Christopher Kirk, Ph.D., the Company’s co-founder and member of the Board, has been appointed to serve as Chief Executive Officer, effective as of the Effective Date.
John Fowler resigned as Chief Executive Officer at Kezar Life Sciences, Inc..
Action
resigned
Role
Chief Executive Officer
Exact text from the filing
On September 30, 2023, John Fowler, the Company’s co-founder, Chief Executive Officer and member of the Board, notified the Board that he will resign and cease serving as Chief Executive Officer, effective November 7, 2023
Kezar Life Sciences, Inc. announced a impairment affecting research and drug discovery activities.
Type
impairment
Affected area
research and drug discovery activities
Exact text from the filing
The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction, including potential impairment charges due to the pausing of the Company’s research and drug discovery activities. However, the Company is not able to estimate the amount or range of amounts of such potential impairments as of the date of this Current Report on Form 8-K.
Kezar Life Sciences, Inc. announced a restructuring with charges of approximately $2.9 million to $3.2 million (approximately 41%).
Type
restructuring
Charge
approximately $2.9 million to $3.2 million
Headcount
approximately 41%
Exact text from the filing
will pause all research and drug discovery activities. The Company anticipates the one-time severance-related charge associated with the workforce reduction to be approximately $2.9 million to $3.2 million. The severance-related charge, which is expected to represent cash expenditures that the Company expects to incur in connection with the workforce reduction, are
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.